BIONTECH SE-ADR (BNTX) Fundamental Analysis & Valuation

NASDAQ:BNTX • US09075V1026

101.5 USD
-0.45 (-0.44%)
At close: Mar 6, 2026
101.5 USD
0 (0%)
After Hours: 3/6/2026, 8:03:20 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BNTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

BNTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. BNTX has an average financial health and profitability rating. BNTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. BNTX Profitability Analysis

1.1 Basic Checks

  • BNTX had negative earnings in the past year.
  • In the past year BNTX has reported a negative cash flow from operations.
  • BNTX had positive earnings in 4 of the past 5 years.
  • Of the past 5 years BNTX 4 years had a positive operating cash flow.
BNTX Yearly Net Income VS EBIT VS OCF VS FCFBNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

  • The Return On Assets of BNTX (-2.68%) is better than 87.12% of its industry peers.
  • BNTX has a Return On Equity of -3.09%. This is amongst the best in the industry. BNTX outperforms 89.04% of its industry peers.
Industry RankSector Rank
ROA -2.68%
ROE -3.09%
ROIC N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
BNTX Yearly ROA, ROE, ROICBNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

  • With an excellent Gross Margin value of 85.62%, BNTX belongs to the best of the industry, outperforming 88.08% of the companies in the same industry.
  • BNTX's Gross Margin has been stable in the last couple of years.
  • BNTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
BNTX Yearly Profit, Operating, Gross MarginsBNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BNTX Health Analysis

2.1 Basic Checks

  • BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BNTX has been increased compared to 1 year ago.
  • BNTX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BNTX is higher compared to a year ago.
BNTX Yearly Shares OutstandingBNTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BNTX Yearly Total Debt VS Total AssetsBNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • BNTX has an Altman-Z score of 6.40. This indicates that BNTX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BNTX (6.40) is better than 75.38% of its industry peers.
  • BNTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • BNTX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: BNTX outperforms 45.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.4
ROIC/WACCN/A
WACC7.42%
BNTX Yearly LT Debt VS Equity VS FCFBNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 7.12 indicates that BNTX has no problem at all paying its short term obligations.
  • BNTX has a Current ratio of 7.12. This is in the better half of the industry: BNTX outperforms 70.00% of its industry peers.
  • BNTX has a Quick Ratio of 7.02. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of BNTX (7.02) is better than 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 7.12
Quick Ratio 7.02
BNTX Yearly Current Assets VS Current LiabilitesBNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BNTX Growth Analysis

3.1 Past

  • The earnings per share for BNTX have decreased strongly by -20.92% in the last year.
  • The Revenue has been growing slightly by 3.70% in the past year.
  • BNTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 90.73% yearly.
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.52% on average over the next years.
  • BNTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.93% yearly.
EPS Next Y-19.54%
EPS Next 2Y-13.54%
EPS Next 3Y-6.16%
EPS Next 5Y5.52%
Revenue Next Year4.52%
Revenue Next 2Y-0.07%
Revenue Next 3Y0.93%
Revenue Next 5Y0.93%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BNTX Yearly Revenue VS EstimatesBNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
BNTX Yearly EPS VS EstimatesBNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. BNTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BNTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTX Price Earnings VS Forward Price EarningsBNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTX Per share dataBNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • A cheap valuation may be justified as BNTX's earnings are expected to decrease with -6.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.54%
EPS Next 3Y-6.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNTX Dividend Analysis

5.1 Amount

  • BNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNTX Fundamentals: All Metrics, Ratios and Statistics

BIONTECH SE-ADR

NASDAQ:BNTX (3/6/2026, 8:03:20 PM)

After market: 101.5 0 (0%)

101.5

-0.45 (-0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-10
Inst Owners20.52%
Inst Owner Change-12.99%
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap24.41B
Revenue(TTM)3.15B
Net Income(TTM)-571.60M
Analysts81.43
Price Target140.76 (38.68%)
Short Float %4.61%
Short Ratio5.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.13%
Min EPS beat(2)21.85%
Max EPS beat(2)44.42%
EPS beat(4)4
Avg EPS beat(4)77.6%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)44.65%
EPS beat(12)9
Avg EPS beat(12)207.14%
EPS beat(16)12
Avg EPS beat(16)164.98%
Revenue beat(2)2
Avg Revenue beat(2)63.4%
Min Revenue beat(2)55.06%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)33.69%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)5
Avg Revenue beat(8)18.96%
Revenue beat(12)6
Avg Revenue beat(12)5.54%
Revenue beat(16)9
Avg Revenue beat(16)12.1%
PT rev (1m)0.98%
PT rev (3m)1.34%
EPS NQ rev (1m)-69.05%
EPS NQ rev (3m)61.29%
EPS NY rev (1m)-0.57%
EPS NY rev (3m)30.88%
Revenue NQ rev (1m)-0.88%
Revenue NQ rev (3m)-1.18%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)24.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.66
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-2.75
EYN/A
EPS(NY)-4.16
Fwd EYN/A
FCF(TTM)-5.29
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS15.23
BVpS89.28
TBVpS80.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.68%
ROE -3.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.62%
FCFM N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 202.92%
Cap/Sales 24.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.12
Quick Ratio 7.02
Altman-Z 6.4
F-Score3
WACC7.42%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
EPS Next Y-19.54%
EPS Next 2Y-13.54%
EPS Next 3Y-6.16%
EPS Next 5Y5.52%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
Revenue Next Year4.52%
Revenue Next 2Y-0.07%
Revenue Next 3Y0.93%
Revenue Next 5Y0.93%
EBIT growth 1Y-6.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.3%
EBIT Next 3Y9.23%
EBIT Next 5Y19.64%
FCF growth 1Y-123.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.92%
OCF growth 3Y-38.43%
OCF growth 5YN/A

BIONTECH SE-ADR / BNTX FAQ

Can you provide the ChartMill fundamental rating for BIONTECH SE-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to BNTX.


What is the valuation status of BIONTECH SE-ADR (BNTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (BNTX). This can be considered as Overvalued.


How profitable is BIONTECH SE-ADR (BNTX) stock?

BIONTECH SE-ADR (BNTX) has a profitability rating of 4 / 10.


What is the expected EPS growth for BIONTECH SE-ADR (BNTX) stock?

The Earnings per Share (EPS) of BIONTECH SE-ADR (BNTX) is expected to decline by -19.54% in the next year.


How sustainable is the dividend of BIONTECH SE-ADR (BNTX) stock?

The dividend rating of BIONTECH SE-ADR (BNTX) is 0 / 10 and the dividend payout ratio is 0%.